Desk Review and Recommendations for Private Sector Engagement
What We Know, What We Don’t Know, and What We Need to Do
PLOS ONE | www.plosone.org 1
January 2014 | Volume 9 | Issue 1 | e86616
The mandate of the National Tuberculosis Control Programme is to provide leadership and stewardship to accelerate intense and coordinated efforts to reduce the adult TB burden of 290 per 100,000 population recently established in the 2013 National TB Prevalence Survey. Other key challenges are low T...B case notification, unacceptably high TB death rates, low antiretroviral therapy (ART) coverage among TB/HIV patients and low drug-resistant notification and treatment.
more
July 2014
This report was made possible through support provided by the One Million Community Health Workers Campaign, mPowering Frontline Health Workers, Intel, and USAID. This report was authored by Cindil Redick for mPowering Frontline Health Workers under the terms of Contract No. GHS-A-00-08...-00002-00. The opinions expressed herein are those of the authors and do not necessarily reflect the views of USAID.
more
AUDIT REPORT NO. 9-000-11-001-P | February 24, 2011
Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. This disease is highly endemic in some regions of North America, Central America, and South America and is also reported in certain countries of Asia and Africa. It often affects people with impaired immunity, including people ...living with HIV, among whom the most frequent clinical presentation is disseminated histoplasmosis. The symptoms of disseminated histoplasmosis are non-specific and may be indistinguishable from those of other infectious diseases, especially disseminated tuberculosis (TB), thus complicating diagnosis and treatment. Histoplasmosis is one of the most frequent opportunistic infections caused by fungal pathogens among people living with HIV in the Americas and may be responsible for 5–15% of AIDS-related deaths every year in this Region. These guidelines aim to provide recommendations for the diagnosis, treatment, and management of disseminated histoplasmosis in persons living with HIV
more
Advance Copy
Accessed: 08.03.2020
Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
WHO and UNITAID
in collaboration with IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) network, PENTA (Paediatric European Network for Treatment of AIDS) foundation and experts from the Paediatric Antiretroviral Working Group
2018 Progress Report
PEPFAR Strategy for Accelerating HIV/AIDS Epidemic Control (2017-2020)
BMJ,Dodd PJ, et al. Thorax 2017;72:559–575. doi:10.1136/thoraxjnl-2016-209421